Breast Cancer Patients Desire Early, Frequent Financial Screening
Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
Many breast cancer patients would prefer their providers financially screen them throughout the treatment process, according to the results of a recent study called Financial Toxicity Screening Preferences in Patients With Breast Cancer.
“Most of our screening is done a single time or maybe twice, it's not something that we do longitudinally,” Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University and co-author said in an interview with Managed Healthcare Executive. “These patient voices can really tell us how we should start changing and what we should start doing differently to be able to incorporate patient voices better.”
Gharzai and her colleagues recently published the results of their study in the Journal of Clinical Oncology. The research team sent an anonymous survey to email subscribers of the nationwide breast cancer–specific philanthropic organization The Pink Fund, asking about financial toxicity screening preferences. Results revealed that patients preferred financial screening conversations be initiated by their providers (83%), happen early (at diagnosis, 45%; when treatment is selected, 37%) and once a month (36%).
How Financial Toxicity Screening Can Be Incorporated Into Everyday Healthcare in America
November 15th 2024Breast cancer treatment settings prove to be a good opportunity to talk about financial toxicity. These conversations can also happen in generalized healthcare, according to Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
Read More
Patient Advocacy Groups and Caretaker Diversity in Metastatic Breast Cancer Research
October 22nd 2024Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes in Metastatic Breast Cancer Care Delivery, shares the reasons why she chose to study metastatic breast cancer patients.
Read More
Differences in Defining 'Clinically Meaningful' in Metastatic Breast Cancer Care
October 4th 2024Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute, explains the importance of the term “clinically meaningful” and shares some of the ways it can be defined.
Read More
